Loading
A phase 1 trial of Pamlectabart tismanitin run by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., now recruiting.
Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT07529782 by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., with 15 participants planned, started 2026-03-17. Conditions recorded: Multiple Myeloma and Other Plasma Cell Neoplasms. Interventions recorded: HDP-101.
Shares Pamlectabart tismanitin, Heidelberg Pharma, Multiple myeloma and the tag pipeline.
Shares Heidelberg Pharma and the tag pipeline.
Shares Heidelberg Pharma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/